A practical reference on PT-141 code: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
A person with type 1 diabetes should balance insulin delivery to manage their blood glucose level. Occasionally, insufficient insulin can result in hyperglycemia. The appropriate response is to take a correction dose of insulin to reduce the blood sugar level and to consider adjusting the insulin regimen to deliver additional insulin in the future to prevent hyperglycemia. Conversely, excessive insulin delivery may result in hypoglycemia. The appropriate response is to treat the hypoglycemia and to consider adjusting the regimen to reduce insulin in the future. Somogyi and others have claimed that if prolonged hypoglycemia is untreated, then stress due to low blood sugar can result in a high blood glucose rebound. The physiological mechanisms driving the rebound are defensive. When the blood glucose level falls below normal, the body responds by releasing the endocrine hormone glucagon as well as the stress hormones epinephrine, cortisol and growth hormone. Glucagon facilitates release of glucose from the liver that raises the blood glucose immediately; the stress hormones cause insulin resistance for several hours, sustaining the elevated blood sugar.
=== Merger with Carl's Jr. and aftermath === In April 1997, CKE Restaurants Holdings, Inc., the parent company of Carl's Jr., bought Hardee's from Imasco for $327 million. The merger created a chain of 3,828 restaurants – 3,152 Hardee's outlets in 40 states and 10 foreign countries and 676 Carl's Jr. outlets primarily in California. Initially, the plan was for the larger Hardee's chain to completely rebrand as Carl's Jr but continue to offer Hardee's existing breakfast menu branded as "Hardee's breakfast" (due to Hardee's stronger sales during breakfast hours, unusual among fast food chains), and even ran a test by rebranding Hardee's locations in the Peoria, Illinois and Oklahoma City, Oklahoma markets as Carl's Jr. However, by 1999 CKE instead rebranded Hardee's into the Carl's Jr. imaging including the Happy Star logo and parts of its lunch menu but kept the Hardee's name and left the breakfast menu intact, though the Oklahoma City locations kept the Carl's Jr. branding permanently. In 1998, Hardee's acquired 557 of the franchised restaurants from Advantica Restaurant Group. In 2001, Hardee's headquarters moved to St. Louis, Missouri. In 2005, Hardee's introduced Hand-Scooped Ice Cream Shakes & Malts. In 2007, CKE Restaurants sold 34 Hardee's locations in North Carolina to longtime franchisee Boddie-Noell Enterprises. In 2008, CKE Restaurants sold 23 Hardee's restaurants in Indiana and Ohio to Midwest First Star, and nine in Davenport, Iowa to Westar Foods. In September 2013, it was announced that Hardee's would expand into the Northeastern United States.
=== Indications === Levosimendan is indicated for inotropic support in acutely-decompensated severe congestive heart failure in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Some of the Phase III studies in the extensive clinical program including the trials LIDO (200 patients), RUSSLAN (500), REVIVE-I (100), REVIVE-II (600) and SURVIVE (1350). In total, the clinical data base includes more than 3500 patients in Phase IIb and III double-blind randomized studies. In the SURVIVE study, despite a reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days. However, in a retrospective subgroup analysis, Levosimendan was superior to dobutamine for treating patients with a history of CHF or those on beta-blocker therapy when they were hospitalized with acute decompensations.
David L. Eaton (born August 15, 1952) is an American toxicologist and professor Emeritus at the University of Washington (UW). His work focuses on risk assessment, gene-environment interactions, environmental carcinogenesis, and xenobiotic biotransformation. Over his career, Eaton has chaired committees for the National Academies of Sciences, Engineering, and Medicine (NASEM), held academic administration positions at the University of Washington, and presided over the Society of Toxicology (SOT).
Sources: en.wikipedia.org
DAMPs can trigger re-epithelialization upon kidney injury, contributing to epithelial–mesenchymal transition, and potentially, to myofibroblast differentiation and proliferation. These discoveries suggest that DAMPs drive not only immune injury, but also kidney regeneration and renal scarring. For example, TLR2-agonistic DAMPs activate renal progenitor cells to regenerate epithelial defects in injured tubules. TLR4-agonistic DAMPs also induce renal dendritic cells to release IL-22, which also accelerates tubule re-epithelialization in acute kidney injury. Finally, DAMPs also promote renal fibrosis by inducing NLRP3, which also promotes TGF-β receptor signaling.
=== Pharmacokinetics === The extent of absorption of cocaine into the circulatory system after nasal insufflation is similar to that after oral ingestion. The rate of absorption after nasal insufflation is limited by cocaine-induced vasoconstriction of capillaries in the nasal mucosa. Onset of absorption after oral ingestion is delayed because cocaine is a weak base with a pKa of 8.6, and is thus in an ionized form that is poorly absorbed from the gastric acid and easily absorbed from the alkaline duodenum. The rate and extent of absorption from inhalation of cocaine is similar or greater than with intravenous injection, as inhalation provides access directly to the capillary bed. The delay in absorption after oral ingestion may account for the popular belief that cocaine bioavailability from the stomach is lower than after insufflation. Compared with ingestion, the faster absorption of insufflated cocaine results in quicker attainment of maximum drug effects. Snorting cocaine produces maximum physiological effects within 40 minutes and maximum psychotropic effects within 20 minutes. Physiological and psychotropic effects from nasally insufflated cocaine are sustained for approximately 40–60 minutes after the peak effects are attained. Cocaine crosses the blood–brain barrier via both a proton-coupled organic cation antiporter and (to a lesser extent) via passive diffusion across cell membranes. As of September 2022, the gene or genes encoding the human proton-organic cation antiporter had not been identified.
=== Gas chromatography with mass spectrometry (GC-MS) === Gas chromatography with mass spectrometry (GC-MS) is considered the gold standard for VOC analysis to identify specific compounds. The chromatography separates the sample mixture in a gaseous state by forcing them through a column using a carrier gas, and the mass spectrometer identifies the compound. The limitation of this method is the requirement of expensive specialized equipment and highly trained personnel. VOC analysis is seen in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), chronic obstructive sleep apnea (OSA), inflammatory bowel disease, cancer, infections, and among others.
The significance of these additional actions for Auvelity's antidepressant effects remains unclear. The combined pharmacological actions of DXM and bupropion make Auvelity function similarly to an SNDRI (serotonin-norepinephrine-dopamine reuptake inhibitor), simultaneously enhancing all three monoamine neurotransmitter systems. This characteristic may contribute to its relatively rapid antidepressant onset. The role of NMDA antagonism in Auvelity appears to be relatively limited. Ketamine and related compounds do indeed owe their rapid antidepressant effects to NMDA receptor antagonism. However, subsequent studies of numerous NMDA antagonists have found that most do not exhibit antidepressant efficacy. The reason appears to be that antidepressant activity requires exceptionally stringent molecular properties for NMDA receptor antagonism, particularly highly specific receptor-binding kinetics. In practice, neither DXM nor dextrorphan fulfills these requirements. This likely explains why Auvelity requires approximately 8 days to produce antidepressant effects, whereas esketamine can begin working within only a few hours. Therefore, although Auvelity substantially shortens the onset of action compared with conventional oral antidepressants, its mechanism underlying the accelerated antidepressant response appears to have only a limited relationship to the rapid antidepressant mechanism of ketamine.
=== January === 2 January – Three people are killed after a fire breaks out at the New County Hotel in Perth. 16 January Teachers in Scotland begin 16 days of "rolling" strike action, with strikes occurring in two local authorities each day, beginning with Glasgow and East Lothian. The UK government announces it will block the Gender Recognition Reform (Scotland) Bill amid concerns about its impact on UK-wide equality law. 23 January – A fire breaks out in former department store Jenners on Princes Street, Edinburgh, resulting in the death of a firefighter and the injury of four others. 24 January – Following a trial at the High Court of Glasgow, transgender woman Isla Bryson is convicted of raping two women in 2016 and 2019, the offences having been committed before she began gender reassignment therapy. She is remanded to Cornton Vale women's prison, but moved to HMP Edinburgh two days later after First Minister Nicola Sturgeon says Bryson will not be allowed to serve her sentence at Cornton Vale. 28 January – Following controversy over the Isla Bryson case, the Daily Record reports that Tiffany Scott, a trans woman subject to an Order for Lifelong Restriction for stalking a 13-year-old girl, has successfully applied for a transfer from a men's prison to a women's facility. The Scottish Conservatives urge the Scottish Government to halt the move. 29 January – The Scottish Prison Service pauses the movement of all transgender prisoners while it carries out an "urgent review" into the transgender cases held in its custody.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.